Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Motion for Lone Pine Order In Fosamax Jaw Lawsuits Denied August 29, 2013 Austin Kirk Add Your Comments The U.S. District Judge presiding over all federal Fosamax jaw injury lawsuits has rejected a request filed by Merck to issue a second “Lone Pine” order, declining the attempt to require plaintiffs to provide additional information to substantial their case as part of the coordinated pretrial proceedings in the federal multidistrict litigation (MDL). Merck currently faces nearly 1,000 lawsuits in the federal court system involving plaintiffs who allege that they suffered severe and debilitating jaw damage from side effects of Fosamax. All cases filed in U.S. District Courts throughout the country are currently consolidated before U.S. District Judge John F. Keegan in the Southern District of New York for coordinated pretrial proceedings as part of an MDL. The centralized management of the case is designed to streamline the litigation and move the cases toward settlement agreements or eventual disposition. Learn More About Fosamax Lawsuit Side effects of Fosamax linked to a risk of sudden femur fractures, severe jaw damage and other problems. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Fosamax Lawsuit Side effects of Fosamax linked to a risk of sudden femur fractures, severe jaw damage and other problems. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Following a series of early Fosamax trials held in the MDL, which are known as “bellwether” cases because they are designed to help the parties gauge how juries are likely to respond to certain evidence and testimony that may be repeated throughout the litigation, Judge Keegan has recently suggested that he may begin remanding hundreds of Fosamax jaw cases back to the U.S. District Courts where they were originally filed for individual disposition. Since the parties have been unable to reach settlements in the Fosamax lawsuits, plaintiffs have pushed for the large-scale remand of lawsuits for individual trial dates, as the coordinated pretrial discovery that applies to all cases has been completed. However, Merck has opposed the bulk remand of cases, seeking to avoid individual trials throughout the country. On August 22, Judge Keegan issued an Order (PDF) denying Merck’s recent motion for the MDL Court to issue a second “Lone Pine” order, which would have required plaintiffs to produce additional evidence and expert testimony to support their claims if they took Fosamax for less than one year, have failed to produce medical records establishing a diagnosis of osteonecrosis of the jaw (ONJ) or if their last use of Fosamax was more than three years before they suffered a jaw injury. “Lone Pine” orders, which get their name from the 1986 New Jersey case of Lore v. Lone Pine Corp., are case management orders that are occasionally issued in mass tort proceedings to require individual plaintiffs to provide additional evidence to support their claim prior to the completion of case-specific discovery and the filing of individual summary judgment motions. In November 2012, Judge Keenan did agree to issue a “Lone Pine” order in the Fosamax litigation that called for plaintiffs who were not claiming an injury involving osteomyelitis or osteonecrosis of the jaw from Fosamax to produce expert reports that supported their claim. That first “Lone Pine” order was designed to identify plaintiffs with “non-specific” diagnosis and to determine whether they fit the criteria for inclusing in the MDL. About 439 plaintiffs were affected by the limited scope of that order, and approximately 430 of those cases were ultimately dismissed from the Fosamax litigation. In rejecting Merck’s request for a second “Lone Pine” order, which could have impacted nearly two thirds of the remaining cases, Judge Keenan determined that it would be inappropriate at this stage of the MDL. Judge Keenan raised questions about the categories of claims proposed by Merck, finding that the Court could not objectively single out plaintiffs without a diagnosis of ONJ, since medical records are not always interpreted the same way. In addition, Judge Keenan did not see any benefit in identifying plaintiffs who used Fosamax for less than one year or failed to use the medication within three years of their diagnosis, since the Court has previously determined that a reasonable jury could believe that short term use of Fosamax may cause ONJ and the American Association of Oral and Maxillofacial Surgeons’ (AAOMS) definition for bisphosphonate-related ONJ does not require prior use of the medication for a certain number of years. “Merck now seeks a Lone Pine order that would require the Court to direct extra scrutiny on certain plaintiffs based on fact-based judgments regarding the affected exposures to Fosamax or the interpretation of medical records – i.e., that plaintiffs whose Fosamax use was more attenuated from onset of ONJ are likely to lose,” wrote Judge Keenan in rejecting the motion. “This is a matter for summary judgment, not for Lone Pine.” Fosamax Litigation Fosamax (alendronate sodium) is a blockbuster medication that was introduced by Merck in 1995, for treatment and prevention of osteoporosis. Before it became available as a generic in 2008, the medication generated over $3 billion in annual sales and was used by millions of Americans. Merck has been fighting Fosamax lawsuits for more than seven years, including claims from users who suffered jaw damage, as well as lawsuits brought by those who suffered spontaneous femur fractures following use of the medication. Thousands of cases pending in state and federal courts throughout the United States allege that Merck also failed to adequately warn about the risk of femur fractures from Fosamax, claiming that users of the drug suffered atypical fractures that occurred following little or no trauma, such as falling from standing height or less. Most of these complaints have been filed since late 2010, when the FDA required Merck to add new warnings about the risk of Fosamax bone fractures. These warnings provided new information for consumers and the medical community about the importance of identifying symptoms of new hip or groin pain, which could occur before an atypical fracture of the femur. The lawsuits allege that Merck knew or should have known about these risks long before the warnings were provided, and claim that if adequate information had been provided to users and the medical community plaintiffs could have avoided suffering complete fractures on Fosamax by avoiding the medication or stopping use earlier. Last year, the FDA issued new recommended guidelines for taking Fosamax and other similar oral bisphophonate medications, such as Actonel and Boniva. The agency suggested that users should consider limiting the medications to a three to five year period, which may allow individuals to reduce the risks of side effects associated with long-term use, while continuing to receive benefits for osteoporosis. In May 2011, the U.S. JPML established a separate MDL proceeding for all Fosamax fracture lawsuits, which have been assigned to U.S. District Judge Garrett E. Brown, Jr. in the District of New Jersey. There are currently about 1,100 cases pending before Judge Brown. Tags: Bisphosphonates, Fosamax, Fosamax Fracture, Merck, ONJ, Osteonecrosis of the Jaw Image Credit: | More Fosamax Lawsuit Stories Fosamax Fracture Lawsuits Dismissed Again, After Judge Rules FDA Rejected Label Warning Change March 24, 2022 Zometa Side Effects Increase Risk of Osteonecrosis of the Jaw: Study January 14, 2021 Study Questions Whether Fosamax And Similar Bone Drugs Provide Benefits After Seven Years of Use December 10, 2020 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 3 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025) Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 4 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025) BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 5 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)
Fosamax Fracture Lawsuits Dismissed Again, After Judge Rules FDA Rejected Label Warning Change March 24, 2022
Study Questions Whether Fosamax And Similar Bone Drugs Provide Benefits After Seven Years of Use December 10, 2020
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 3 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 4 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)
BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 5 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)